Palo Alto Investors LP 13F Holdings · Q2 2026
Palo Alto Investors LP reported 52 securities worth $723.72M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: PTCT (10.36%), ACAD (10.01%), INSM (6.10%). Among its top 25 positions this quarter: 1 new, 4 added, 11 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PTCT | PTC THERAPEUTICS INC | $75.0M | 10.36% | 918,846 | Trimmed |
| 2 | ACAD | ACADIA PHARMACEUTICALS INC | $72.5M | 10.01% | 2.9M | Trimmed |
| 3 | INSM | INSMED INC | $44.1M | 6.10% | 413,980 | Trimmed |
| 4 | MIRM | MIRUM PHARMACEUTICALS INC | $40.8M | 5.64% | 348,808 | Added |
| 5 | ANAB | ANAPTYSBIO INC | $40.7M | 5.63% | 603,489 | Trimmed |
| 6 | BMRN | BIOMARIN PHARMACEUTICAL INC | $39.1M | 5.40% | 682,777 | Trimmed |
| 7 | DYN | DYNE THERAPEUTICS INC | $36.6M | 5.06% | 1.6M | Trimmed |
| 8 | UTHR | UNITED THERAPEUTICS CORP | $33.9M | 4.69% | 62,587 | Trimmed |
| 9 | IRON | DISC MEDICINE INC | $30.5M | 4.21% | 416,646 | Added |
| 10 | BIIB | BIOGEN INC | $30.3M | 4.19% | 140,279 | Trimmed |
| 11 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $22.0M | 3.04% | 5.3M | Trimmed |
| 12 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $19.9M | 2.75% | 596,495 | Hold |
| 13 | NVCR | NOVOCURE LTD | $19.4M | 2.68% | 1.3M | Hold |
| 14 | SNDX | SYNDAX PHARMACEUTICALS INC | $18.9M | 2.61% | 864,986 | Hold |
| 15 | ANNX | ANNEXON INC | $16.8M | 2.33% | 2.9M | Hold |
| 16 | BCAX | BICARA THERAPEUTICS INC | $16.3M | 2.26% | 550,408 | Hold |
| 17 | CDNA | CAREDX INC | $15.2M | 2.09% | 531,870 | Hold |
| 18 | CLDX | CELLDEX THERAPEUTICS INC | $14.9M | 2.06% | 399,856 | Added |
| 19 | ALKS | ALKERMES PLC | $12.7M | 1.76% | 242,560 | Hold |
| 20 | CMPX | COMPASS THERAPEUTICS INC | $12.8M | 1.76% | 5.8M | Added |
| 21 | TRAX | FIRST TRACKS BIOTHERAPEUTICS | $12.1M | 1.68% | 603,489 | New |
| 22 | PRTA | PROTHENA CORP PLC | $11.2M | 1.55% | 1.1M | Trimmed |
| 23 | TVTX | TRAVERE THERAPEUTICS INC | $9.5M | 1.32% | 167,525 | Trimmed |
| 24 | TSHA | TAYSHA GENE THERAPIES INC | $9.5M | 1.31% | 1.4M | Hold |
| 25 | ACRS | ACLARIS THERAPEUTICS INC | $8.5M | 1.18% | 1.6M | Hold |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR